Esperion Therapeutics, Inc.
ESPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $411,800 | $308,289 | $413,717 | $144,513 |
| - Cash | $144,761 | $82,248 | $124,775 | $208,892 |
| + Debt | $591,212 | $540,947 | $260,948 | $260,196 |
| Enterprise Value | $858,251 | $766,988 | $549,890 | $195,817 |
| Revenue | $332,314 | $116,334 | $75,475 | $78,447 |
| % Growth | 185.7% | 54.1% | -3.8% | – |
| Gross Profit | $263,713 | $73,067 | $48,508 | $64,230 |
| % Margin | 79.4% | 62.8% | 64.3% | 81.9% |
| EBITDA | $7,569 | -$150,108 | -$176,349 | -$222,143 |
| % Margin | 2.3% | -129% | -233.7% | -283.2% |
| Net Income | -$51,745 | -$209,248 | -$233,659 | -$269,108 |
| % Margin | -15.6% | -179.9% | -309.6% | -343% |
| EPS Diluted | -0.28 | -2.03 | -4.33 | -11.03 |
| % Growth | 86.2% | 53.1% | 60.7% | – |
| Operating Cash Flow | -$23,654 | -$135,487 | -$174,827 | -$263,809 |
| Capital Expenditures | -$317 | $0 | $0 | $0 |
| Free Cash Flow | -$23,971 | -$135,487 | -$174,827 | -$263,809 |